The post-treatment tumor bed of patients with MPR was enriched with T cell clones that had peripherally expanded between weeks 2–4 after anti-PD-1, and the intratumoral space occupied by these clonotypes was inversely correlated with percent residual tumor. The gene discussed is PDCD1; the disease is neoplasm.